STOCK TITAN
  1. Home
  2. News
  3. JAGX

Jaguar Health Inc Stock Price, News & Analysis

JAGX Nasdaq

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Jaguar Health Inc (NASDAQ: JAGX) delivers innovative plant-based therapeutics for gastrointestinal health across human and animal populations. This news hub provides investors and healthcare professionals with essential updates about the company’s clinical developments, regulatory milestones, and sustainable pharmaceutical innovations.

Access official press releases and verified news covering key areas including FDA approvals for Mytesi® (crofelemer), veterinary health product developments like Canalevia™, clinical trial progress, and strategic partnerships. Our curated collection ensures timely updates on JAGX’s advancements in non-opioid anti-secretory treatments and ecological sourcing practices.

Discover updates across multiple categories: new product launches, research collaborations, financial disclosures, intellectual property developments, and sustainability initiatives. Each update is vetted for accuracy, providing reliable insights into Jaguar Health’s progress in addressing chronic diarrhea conditions and neglected gastrointestinal disorders.

Bookmark this page for streamlined access to Jaguar Health’s latest developments. Check back regularly for updates on their unique approach to combining traditional botanical knowledge with modern pharmaceutical science through subsidiaries like Napo Pharmaceuticals.

News

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has announced the extension of maturity date for its convertible promissory notes from June 30, 2025 to January 30, 2026. The extension applies to approximately $2.57 million in aggregate principal amount from the original $3.448 million bridge financing that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million (including accrued interest) into company equity.

The bridge financing participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors. The funding aims to support Jaguar's three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none
-
News

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reports progress in its orphan disease intestinal failure program for crofelemer. The Phase 2 study for microvillus inclusion disease (MVID) in pediatric patients has reached 25% enrollment, while the SBS-IF study in adults is above 10%. Initial proof-of-concept results show crofelemer reduced total parenteral nutrition requirements by up to 27% in MVID patients and 12.5% in short bowel syndrome patients. The company expects to complete its randomized Phase 2 MVID study by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize its intestinal failure products, aiming to generate non-dilutive funding. The positive early results could potentially support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program, potentially accelerating regulatory approval pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
-
News

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced that its founder, president and CEO Lisa Conte will deliver a virtual presentation at the Emerging Growth Conference on June 18, 2025, from 9:40 - 10:10 AM Eastern Time. The presentation will be available online, with a replay accessible through EmergingGrowth.com and the Emerging Growth YouTube Channel. This conference presentation aims to provide updates on near-term catalysts for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
none
News

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) has established the first study site for its field study of Canalevia-CA1, an FDA conditionally approved prescription drug for treating chemotherapy-induced diarrhea (CID) in dogs. The company has two main objectives: obtaining full FDA approval for CID treatment and expanding the drug's indication to treat general, non-infectious diarrhea in dogs. Jaguar is actively seeking partners to fund development and commercialization of the drug for the broader diarrhea indication. The market opportunity is significant, with approximately 6 million annual cases of acute and chronic diarrhea in dogs seen by U.S. veterinarians. The prospective, randomized, open-label field study will collect real-world data on Canalevia-CA1's effectiveness in dogs undergoing chemotherapy. Currently, there are no FDA-approved drugs for treating general diarrhea in dogs, despite it being one of the most common reasons for veterinary visits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
fda approval
-
News

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announces a virtual fireside chat featuring CEO Lisa Conte on June 10, 2025, at 9:00 AM ET as part of Lytham Partners' Spring 2025 Spotlight Series. The discussion will center on the company's recent FDA meeting regarding statistically significant responder analysis results from their Phase 3 OnTarget trial's breast cancer patient subgroup. The company notes that the US metastatic breast cancer population potentially qualifies as an orphan population, aligning with their core focus. Jaguar Health plans to pursue authorization for an expanded access program for breast cancer patients who may not qualify for a potential pivotal treatment trial with crofelemer in metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
News

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reports a productive Type C Meeting with the FDA regarding crofelemer for cancer therapy-related diarrhea (CTD) in metastatic breast cancer patients. The company proposed two pathways: conducting a pivotal treatment trial and initiating an expanded access program. While the Phase 3 OnTarget trial didn't meet its primary endpoint overall, the breast cancer patient subgroup (183 of 287 participants) showed statistically significant improvement in diarrhea response compared to placebo. The company plans to pursue orphan drug designation, as the US metastatic breast cancer population qualifies as an orphan population. Jaguar also intends to seek Breakthrough Therapy and/or Fast Track designation. Crofelemer has been previously commercialized for HIV-related diarrhea since 2012 with no reported serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
clinical trial fda approval
News

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) has announced that its founder, president and CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025, at 9:00 AM Eastern. The event is part of Lytham Partners' Spring 2025 Spotlight Series and will focus on the company's efforts to advance its orphan disease development programs. The one-hour virtual discussion will be available for replay after the event for those unable to attend the live session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
none
-
News

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has announced a $1.5 million registered direct offering priced at-the-market. The company will sell 246,306 shares of common stock at $6.09 per share. Additionally, in a concurrent private placement, Jaguar will issue unregistered warrants to purchase up to 492,612 shares at an exercise price of $5.84 per share, exercisable immediately and expiring within 24 months.

H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is expected to close around May 22, 2025. Jaguar plans to use the net proceeds for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes, and capital expenditures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.05%
Tags
offering
-
News

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) has announced the randomization of the first patient in their Phase 2 clinical trial evaluating crofelemer for pediatric patients with Microvillus Inclusion Disease (MVID). Initial proof-of-concept results from an ongoing investigator-initiated trial in Abu Dhabi showed promising outcomes, with crofelemer reducing total parenteral support by up to 27% in a pediatric MVID patient. The patient's symptoms worsened when taken off the treatment, leading to early reinstatement. The company expects additional proof-of-concept results throughout 2025, with Phase 2 study results anticipated in H2 2026. Given MVID's ultrarare status, positive results even in a small number of patients could potentially lead to expedited approval through the EU's PRIME program and FDA's Breakthrough Therapy designation. Currently, there are no approved drug treatments for MVID, a condition requiring life-sustaining total parenteral nutrition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
News

Jaguar Health Reports First Quarter 2025 Financials

Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reported Q1 2025 financial results with combined net revenue of $2.2 million, showing a 6% decrease from Q1 2024 ($2.4M) and a 37% decline from Q4 2024 ($3.5M). While Mytesi prescription volume increased by 1.8% YoY, it decreased 13.5% QoQ. The company's net loss widened to $10.4 million compared to $9.2 million in Q1 2024. Key operational highlights include proof-of-concept results showing crofelemer reduced total parenteral nutrition in MVID and SBS-IF patients by up to 27% and 12.5%. R&D expenses decreased by $0.6M to $3.7M, while Sales & Marketing expenses increased by $1.1M to $2.5M. The company's non-GAAP Recurring EBITDA loss increased to $9.7 million from $8.8 million in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
earnings

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $1.77 as of August 27, 2025.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 3.9M.
Stock JAGX logo
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

#6407 Ranked by Market Cap
N/A Ranked by Dividends

JAGX Stock Data

3.89M
2.02M
7.17%
4.4%
2.3%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO